GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Net-Net Working Capital

Arctic Bioscience AS (OSL:ABS) Net-Net Working Capital : kr0.22 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Arctic Bioscience AS's Net-Net Working Capital for the quarter that ended in Jun. 2024 was kr0.22.

The industry rank for Arctic Bioscience AS's Net-Net Working Capital or its related term are showing as below:

OSL:ABS's Price-to-Net-Net-Working-Capital is ranked worse than
87.24% of 901 companies
in the Biotechnology industry
Industry Median: 3.81 vs OSL:ABS: 20.05

Arctic Bioscience AS Net-Net Working Capital Historical Data

The historical data trend for Arctic Bioscience AS's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS Net-Net Working Capital Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial 0.92 0.15 9.23 5.36 2.38

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 7.41 5.36 4.17 2.38 0.22

Competitive Comparison of Arctic Bioscience AS's Net-Net Working Capital

For the Biotechnology subindustry, Arctic Bioscience AS's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arctic Bioscience AS's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Arctic Bioscience AS's Price-to-Net-Net-Working-Capital falls into.


;
;

Arctic Bioscience AS Net-Net Working Capital Calculation

Arctic Bioscience AS's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(78.471+0.75 * 9.611+0.5 * 32.794-41.694
-0-0)/25.370
=2.38

Arctic Bioscience AS's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2024 is calculated as

Net-Net Working Capital(Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(19.831+0.75 * 11.373+0.5 * 30.626-38.116
-0-0)/25.370
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Arctic Bioscience AS  (OSL:ABS) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Arctic Bioscience AS Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Arctic Bioscience AS Business Description

Traded in Other Exchanges
Address
Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand. The company operates in Norway, Europe, Australia and APAC.

Arctic Bioscience AS Headlines

No Headlines